IFRX - InflaRx N.V. logo

IFRX

InflaRx N.V.

Rev —top 1%5Y
Hold

InflaRx N.V. is a biopharmaceutical company that develops C5a inhibitors to treat autoimmune and inflammatory diseases. Its lead candidate, vilobelimab, is in Phase 3 trials for early septic organ dysfunction, with additional candidates in development.

⚕️ Healthcare NASDAQ Listed 2017 € EUR
$1,000 invested 5 years ago $817today

Score Overview

1 Year
Score
Net Growth14.22%
Net TrendGrew
Net Income Consistency
Rev Growth-134.44%
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth14.21%
Net Trend60%
Net Income Consistency
Rev Growth
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-61.50%
Net Trend44%
Net Income Consistency
Rev Growth-104.37%
Rev Trend22%
Revenue Consistency

See the full market ranking →

InflaRx N.V. fundamental performance

Across InflaRx N.V.'s full reported history, from 2017 to 2025, revenue declined from € 231K to € 29.33K and net income went from -€ 24M to -€ 45M. Revenue increased in 22% of the years measured; net income in 44%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.01
1 Year2025-08-12
$ 0.83141.30%
5 Years2021-08-12
$ 2.46-18.29%
All Time2017-11-08
$ 14.99-86.59%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026-€ 10.1K-€ 39M€ 158M
2025€ 29.33K-€ 45M€ 46M
2024€ 165.79K-€ 46M€ 18M
2023€ 63.09K-€ 42M€ 12M
2022€ 0.00-€ 29M€ 81M
2021€ 0.00-€ 45M€ 83M
2020€ 0.00-€ 33M€ 81M
2019€ 0.00-€ 53M€ 115M
2018€ 0.00-€ 29M€ 156M
IPO2017€ 231K-€ 24M€ 123M

Explore beyond IFRX

You're looking at InflaRx N.V.. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies